Running a specialty drug business is hard enough on its own - just ask Salix Pharmaceuticals (Nasdaq:SLXP), Forest Labs (NYSE:FRX) or Warner Chilcott (Nasdaq:WCRX) shareholders - but Endo Health Solutions (Nasdaq:ENDP) decided to up the difficulty level up going deeply into debt to fund a diversification into devices, services and medical records. With generics challenging the branded drug business and improvements needed in the AMS business, this is a tricky stock right now. Although Endo has a good history of generating solid free cash flow, I think investors are justified in questioning management's vision and this isn't an especially compelling stock today.

Forex Broker Guide: Using the right broker is essential when competing in today's forex marketplace.

Disappointing Third Quarter Results Underscore Some Challenges
This wasn't an especially strong quarter for Endo. Revenue fell 1% from last year, missing the average sell-side target by around 5%. The revenue weakness was almost surprisingly even, as all the major units missed. Branded drug sales were 2% lower as 15% growth in Lipoderm was offset by a nearly one-third drop in Opana ER and, frankly, minimal growth outside of Lipoderm. Revenue from the Qualitest generics business was up 12%, while Healthtronics revenue climbed 1%. AMS disappointed again, as sales fell 14% with all three segments showing negative year-on-year comps.

Adjusted gross margin fell about three points, and adjusted operating income was flat. This too was slightly below expectation, and though Endo did beat the average sell-side earnings per share (EPS) estimate, it got a meaningful boost from a lower tax rate and would have otherwise missed.

Not A Lot Of Good News From The Drug Side
Endo is definitely facing some trials and tribulations in the branded drug business. The decision to end further development of Urocidin for bladder cancer was a definite disappointment, though it was likely never going to be even a 10% contributor to segment sales. There are still risks from generics, though, as Impax (Nasdaq:IPXL) is likely to launch a non-tamper resistant form of Opana ER next year and generic Lipoderm could still be on the way in 2013 as well. On the more optimistic side, BEMA Buprenorphine (which Endo is developing with BioDelivery Sciences (Nasdaq:BDSI)) could be a significant contributor in a couple of years, with sales potential in the hundreds of millions if it gets FDA approval. On the Opana ER side, Endo's patents for tamper-resistant formulations should matter, and I believe this drug's sales should recover.

AMS Looking Worse, But Generics Look Good
I didn't like Endo's acquisition of AMS at the time of the deal, and I like it even less now. Although some of the underperformance at AMS is arguably beyond the company's control (and related to FDA warnings regarding surgical mesh), Johnson & Johnson (NYSE:JNJ), C.R. Bard (NYSE:BCR), and Covidien (NYSE:COV) seem to be adapting better. What's more, whatever the excuse, revenue at AMS is now about 80% of what it was before the deal closed; that's not the sort of diversification that Endo needed. On the generics side, Endo should get credit where it's due. This business is growing well in what is not exactly an easy market for generics companies (look at Mylan (Nasdaq:MYL) or Teva (NYSE:TEVA)), and I do see a lot of growth potential even as the pipeline for major branded drugs going off patent in the next two or three years isn't superb.

The Bottom Line
I'd feel better about Endo's prospects if it had a strong tradition of internal new drug discovery and didn't have the acquisition debt that came with its acquisition program. As it is, competing with Pfizer (NYSE:PFE) and Purdue in pain is no trivial manner, nor will turning AMS around be an easy feat. With upcoming generic competition and ongoing challenges in its device business, I could see Endo being one of the few drug/device companies to struggle growing its cash flow over the next five to 10 years. To be fair, that projection includes the assumption that Endo won't be able to match prior free cash flow (FCF) margins in the low 20%'s and will instead convert revenue to free cash flow at a high teens rate. What's more, I think the strange mix of drugs, devices, and services limits the number of potential acquirers. This is a case where I'd love to be wrong, but I don't see a lot of value in these shares today, particularly relative to other specialty drug companies.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. Earnings Per Share - EPS

    The portion of a company's profit allocated to each outstanding ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!